Biomea Fusion (BMEA) Share-based Compensation (2021 - 2026)
Biomea Fusion (BMEA) posted Share-based Compensation of $1.6 million for Q1 2026, up 82.89% sequentially from $865000.0 in Q3 2025.
Biomea Fusion (BMEA) Share-based Compensation (2021 - 2026) Analysis & Trends
Biomea Fusion has reported Share-based Compensation for 6 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Share-based Compensation changed N/A year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 73.25% YoY) and the FY2025 annual result came in at $10.8 million, down 64.47% from the prior year.
- Share-based Compensation grew to $1.6 million in Q1 2026 per BMEA's latest filing, from $865000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $15.4 million in Q2 2025 and troughed at $865000.0 in Q3 2025.
- A 5-year average of $3.3 million and a median of $2.3 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 543.81% in 2025, down 61.79% in 2025.
- Over 5 years, Share-based Compensation stood at $2.7 million in 2022, then dropped by 8.25% to $2.5 million in 2023, then soared by 80.18% to $4.5 million in 2024, then tumbled by 80.73% to $865000.0 in 2025, then surged by 82.89% to $1.6 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.6 million, $865000.0, and $15.4 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 13.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.20 Mn |
| Jun 30, 2026 | 13.20 Mn |
| Mar 31, 2026 | 1.58 Mn |
| Mar 31, 2026 | 1.58 Mn |
| Sep 30, 2025 | 865,000.00 |
| Sep 30, 2025 | 865,000.00 |
| Jun 30, 2025 | 15.40 Mn |
| Jun 30, 2025 | 15.40 Mn |
| Dec 31, 2024 | 4.49 Mn |
| Dec 31, 2024 | 4.49 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Dec 31, 2023 | 2.49 Mn |
| Dec 31, 2023 | 2.49 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.78 Mn |